Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen‐induced seasonal allergic rhinitis

Nagakura, Toshikazu; Ogino, Satoshi; Okubo, Kimihiro; Sato, Norio; Takahashi, Masao; Ishikawa, Takeru

doi:10.1111/j.1365-2222.2007.02894.x

Cited by 56 publications

(33 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These two findings indicate that long-term treatment with suplatast is effective in both TDI-induced and allergen-induced rhinitis. Nagakura et al compared the efficacy and safety of omalizumab, anti-IgE Ab, with suplatast and concluded that omalizumab was more effective than suplatast tosilate against patients with moderate to severe Japanese cedar pollen-induced seasonal allergic rhinitis (56). In such patients, the serum-free IgE level is extremely high, and suppressive effect of omalizumab on the decrease in free IgE level should be much stronger than suplatast.…”

Section: Discussionmentioning

confidence: 99%

Suplatast Tosilate Inhibits Histamine Signaling by Direct and Indirect Down-Regulation of Histamine H1 Receptor Gene Expression through Suppression of Histidine Decarboxylase and IL-4 Gene Transcriptions

Shahriar

Mizuguchi

Maeyama

et al. 2009

The Journal of Immunology

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an inflammatory disorder typified by symptoms such as sneezing, congestion, and rhinorrhea. Histamine plays important roles in eliciting AR symptoms. Up-regulation of the histamine H1 receptor (H1R) and histidine decarboxylase (HDC) mRNAs was observed in AR patients. Th2 cytokines are also involved in the pathogenesis of AR. We examined the effect of suplatast tosilate on nasal symptoms, and H1R, HDC, and IL-4 gene expression using toluene-2,4-diisocyanate (TDI)-sensitized rats and HeLa cells expressing endogenous H1R. Provocation with TDI increased nasal symptoms, HDC activity, the histamine content of nasal lavage fluid, and the expression of H1R, HDC, and IL-4 mRNAs in TDI-sensitized rats. Pretreatment with suplatast for 2 wk significantly suppressed TDI-induced nasal symptoms and elevation of H1R, HDC, and IL-4 mRNAs. Suplatast also suppressed HDC activity in the nasal mucosa and the histamine content of the nasal lavage fluid. Bilateral injection of IL-4 into the nasal cavity of normal rats up-regulated H1R mRNA, while intranasal application of histamine up-regulated IL-4 mRNA. Suplatast suppressed IL-4-induced up-regulation of H1R mRNA in HeLa cells. However, it did not inhibit histamine-induced H1R mRNA elevation. These results suggest that suplatast alleviates nasal symptoms by inhibiting histamine signaling in TDI-sensitized rats through the suppression of histamine- and IL-4-induced H1R gene expression by the inhibitions of HDC and IL-4 gene transcriptions, respectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Suplatast Tosilate Inhibits Histamine Signaling by Direct and Indirect Down-Regulation of Histamine H1 Receptor Gene Expression through Suppression of Histidine Decarboxylase and IL-4 Gene Transcriptions

Shahriar

Mizuguchi

Maeyama

et al. 2009

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Several clinical trials have delineated the efficacy of omalizumab in allergic asthma, rhinitis, food allergy and atopic dermatitis (AD) [42][43][44][45][46][47][48][49][50][51][52][53]. Until today three Cochrane analyses have been performed regarding omalizumab usage [54][55][56].…”

Section: Targeting Ige; Omalizumabmentioning

confidence: 99%

Monoclonal Antibodies in Allergy; Current Applications and Promising Trials

Özdemir¹

2009

IAD

View full text Add to dashboard Cite

Allergic disorders, including asthma, allergic rhinoconjunctivitis, atopic dermatitis, food allergies, urticaria and anaphylaxis have significant impacts on our daily lives. Innovation of novel treatment modalities targeting effector cells, cytokines, receptors or signaling pathways may bring new alternatives in the management of diseases, including allergic disorders. Understanding the mechanisms of allergic immune response is a requisite to plan or switch to a new or an adjunctive treatment course instead of or in addition to current conventional therapies, which are almost effective and safe in most of the cases. Monoclonal antibodies are major candidates that may act on the specific targets of allergic immune response in the treatment of these disorders. As monoclonal antibodies may contribute to our designing of new treatment options within the next years, specific concerns have to be considered such as efficacy, safety, long-term tolerability of these molecules as well as identifying associations with the mechanisms of disease pathogenesis. Hereby, it is aimed to review most of the currently published clinical studies in which some monoclonal antibodies were trialed for the management of allergic disorders. This review also addressed some recently patented monoclonal antibodies and their uses.

show abstract

“…The use of omalizumab for other allergic diseases has not undergone the same level of scrutiny as for allergic asthma, but its effectiveness in the treatment of other atopic diseases has been demonstrated by a number of small studies and case reports (Table I [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] and see also the Reference section in this article's Online Repository at www.jacionline.org).…”

mentioning

confidence: 99%

“…18 Similar efficacy in rhinitis symptom improvement has been demonstrated for other pollens, including birch and Japanese cedar. 1,18 Omalizumab was also shown to be effective in the treatment of perennial allergic rhinitis when patients with moderate-to-severe disease were evaluated. 18 However, the magnitude of the effect was small.…”

mentioning

confidence: 99%

Anti-IgE therapy: Clinical utility beyond asthma

Casale¹,

Stokes²

2009

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen‐induced seasonal allergic rhinitis

Abstract: Omalizumab showed significantly greater improvements than suplatast tosilate in the treatment of SAR induced by Japanese cedar pollens.

Cited by 56 publications

References 38 publications

Suplatast Tosilate Inhibits Histamine Signaling by Direct and Indirect Down-Regulation of Histamine H1 Receptor Gene Expression through Suppression of Histidine Decarboxylase and IL-4 Gene Transcriptions

Suplatast Tosilate Inhibits Histamine Signaling by Direct and Indirect Down-Regulation of Histamine H1 Receptor Gene Expression through Suppression of Histidine Decarboxylase and IL-4 Gene Transcriptions

Monoclonal Antibodies in Allergy; Current Applications and Promising Trials

Anti-IgE therapy: Clinical utility beyond asthma

Contact Info

Product

Resources

About